Ocular Hypertension Market to Expand Significantly by 2034, States DelveInsight Report | Laboratoires Thea, Rigshospitalet, Amneal Pharma, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocu

DelveInsight's "Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ocular Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ocular Hypertension Market Forecast
https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ocular Hypertension Market Report:
• The Ocular Hypertension market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, Qlaris Bio announced positive topline results from two randomized Phase II U.S. trials, Osprey and Apteryx, evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Both masked trials successfully met all primary and secondary endpoints. The Osprey trial specifically assessed the therapy's tolerability, intraocular pressure (IOP)-lowering efficacy, and safety across multiple doses compared to a vehicle in 62 adult participants with POAG or OHT.
• In November 2024, SpyGlass PharmaTM, a privately-owned ophthalmic biotechnology firm, has announced the completion of patient enrollment for its Phase I/II randomized, multi-center, controlled clinical trial (NCT06120842). This trial evaluates the SpyGlass Drug Delivery Platform in individuals with glaucoma or ocular hypertension. The platform is designed to provide long-term bimatoprost delivery, reducing intraocular pressure (IOP), and is implanted during standard cataract surgery.
• In November 2024, MediPrint aims to advance two key programs in 2025. The first targets comfort enhancement in the daily disposable lens market using hyaluronic acid (HA). The second involves launching a Phase 3 clinical trial for LL-BMT1, designed to improve bioavailability, reduce side effects, and enhance patient convenience. LL-BMT1 has the potential to revolutionize the treatment of ocular hypertension and mild to moderate glaucoma.
• The ocular hypertension market is expected to experience consistent growth, with a robust CAGR from 2024 to 2034. This expansion across the 7MM is fueled by the emergence of new treatments like NCX 470, QLS-111, and ST266, as well as an increasingly aging population.
• DelveInsight's epidemiology model estimates that there were around 21 million prevalent cases of ocular hypertension across the 7MM in 2023, with 13 million diagnosed cases. These figures are expected to increase over the study period from 2020 to 2034.
• In 2023, the United States reported the highest number of diagnosed ocular hypertension cases, totaling around 5.4 million.
• In 2023, Germany had the highest number of diagnosed ocular hypertension cases among the EU4 and the UK, with around 1.3 million cases, followed by the UK with approximately 1.1 million cases. Spain had the lowest, reporting nearly 866 thousand cases.
• In 2023, Japan reported approximately 2.7 million diagnosed cases of ocular hypertension, and this figure is anticipated to rise over the course of the study period.
• Key Ocular Hypertension Companies: Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others
• Key Ocular Hypertension Therapies: T4090, Xalatan, Reference - LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others
• The Ocular Hypertension epidemiology based on gender analyzed that females are more affected than males
• The Ocular Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ocular Hypertension pipeline products will significantly revolutionize the Ocular Hypertension market dynamics.

Ocular Hypertension Overview
Ocular hypertension refers to the condition where the pressure inside the eye, known as intraocular pressure (IOP), is higher than normal. This increased pressure can lead to potential damage to the optic nerve, which is crucial for vision. It's important to note that ocular hypertension doesn't always result in glaucoma, but it is considered a significant risk factor for the development of the condition.

Get a Free sample for the Ocular Hypertension Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ocular Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ocular Hypertension Epidemiology Segmentation:
The Ocular Hypertension market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Ocular Hypertension
• Prevalent Cases of Ocular Hypertension by severity
• Gender-specific Prevalence of Ocular Hypertension
• Diagnosed Cases of Episodic and Chronic Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Epidemiology Forecast
https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ocular Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Hypertension market or expected to get launched during the study period. The analysis covers Ocular Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ocular Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ocular Hypertension Therapies and Key Companies
• T4090: Laboratoires Thea
• Xalatan: Rigshospitalet
• Reference - LUMIGAN®: Amneal Pharmaceuticals
• TO-O-1001: Theratocular Biotek Co.
• AR-17043: Alcon Research
• OPC-1085EL: Otsuka Beijing Research Institute
• QLS-111: Qlaris Bio, Inc.
• NCX 470: Nicox Ophthalmics
• Nyxol: Ocuphire Pharma
• Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical
• LL-BMT1: MediPrint Ophthalmics
• PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company
• JV-GL1: JeniVision, Inc.
• NCX 470: Nicox Ophthalmics, Inc.
• Kinezodianone R hydrochloride: Laboratoires Thea
• G2-TR intraocular implant containing travoprost: Glaukos Corporation
• H-1337: D. Western Therapeutics Institute, Inc.
• AGN-193408 SR: AbbVie
• Latanoprost ophthalmic solution: TearClear Corp
• OTX-TIC: Ocular Therapeutix, Inc.
• PER-001: Perfuse Therapeutics, Inc.

Discover more about therapies set to grab major Ocular Hypertension market share @ Ocular Hypertension Treatment Landscape
https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Ocular Hypertension Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ocular Hypertension Companies: Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others
• Key Ocular Hypertension Therapies: T4090, Xalatan, Reference - LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ocular Hypertension Unmet Needs, KOL's views, Analyst's views, Ocular Hypertension Market Access and Reimbursement

To know more about Ocular Hypertension companies working in the treatment market, visit @ Ocular Hypertension Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ocular Hypertension Market Report Introduction
2. Executive Summary for Ocular Hypertension
3. SWOT analysis of Ocular Hypertension
4. Ocular Hypertension Patient Share (%) Overview at a Glance
5. Ocular Hypertension Market Overview at a Glance
6. Ocular Hypertension Disease Background and Overview
7. Ocular Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Ocular Hypertension
9. Ocular Hypertension Current Treatment and Medical Practices
10. Ocular Hypertension Unmet Needs
11. Ocular Hypertension Emerging Therapies
12. Ocular Hypertension Market Outlook
13. Country-Wise Ocular Hypertension Market Analysis (2020-2034)
14. Ocular Hypertension Market Access and Reimbursement of Therapies
15. Ocular Hypertension Market Drivers
16. Ocular Hypertension Market Barriers
17. Ocular Hypertension Appendix
18. Ocular Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Ocular Hypertension Pipeline https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Ocular Hypertension Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ocular Hypertension market. A detailed picture of the Ocular Hypertension pipeline landscape is provided, which includes the disease overview and Ocular Hypertension treatment guidelines.

Ocular Hypertension Epidemiology https://www.delveinsight.com/report-store/ocular-hypertension-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ocular Hypertension Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Ocular Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.